from Breakingviews:

Pfizer’s pricey non-split may only defer problem

September 26, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

GSK tries out alternative medicine with new CEO

September 20, 2016

The author is a Reuters Breakingviews columnist.  The opinions expressed are his own.

from Breakingviews:

Perrigo shows danger of overplaying M&A defense

September 13, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Drugmakers get their $2.3 bln worth in Washington

September 1, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are her own.

from Breakingviews:

Mylan injects adrenaline into healthcare debate

August 25, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Pfizer bets $14 bln it knows better than market

August 22, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Bristol-Myers suffers $21 bln self-inflicted wound

August 5, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Valeant may strain to engineer way out the in door

June 6, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

J&J’s corpulence defense weighs heavy

June 2, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Bayer’s Monsanto bid yields poor financial harvest

May 27, 2016

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.